Clinical trials with crizotinib in ALK+ patients | Download Table
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data | Future Oncology
Ensartinib
Ensartinib Tops Crizotinib in ALK-Positive NSCLC | MedPage Today
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models | Nature Communications
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Crizotinib Shows Promise for Childhood Cancers - NCI
Pharmaceuticals | Free Full-Text | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer | HTML
Main adverse events with crizotinib in clinical trials | Download Table
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) | Molecular Cancer | Full Text
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Virtual clinical trial gives entrectinib edge over crizotinib against ROS1+ non-small cell lung cancer
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Actionable Alterations - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
Phase III trial of crizotinib versus chemotherapy in previously treated... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Crizotinib - Wikipedia
Post-Crizotinib Treatment ALK+ mNSCLC Clinical Trials - ALECENSA® (alectinib)
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial - Journal of Thoracic Oncology
